Related Experiment Video

Updated: Jul 7, 2026

In situ Quantification of Pancreatic Beta-cell Mass in Mice
09:50

In situ Quantification of Pancreatic Beta-cell Mass in Mice

Published on: June 7, 2010

Biphasic response of pancreatic beta-cell mass to ablation of tuberous sclerosis complex 2 in mice

Yutaka Shigeyama1, Toshiyuki Kobayashi, Yoshiaki Kido

  • 1Department of Internal Medicine, Division of Diabetes, Metabolism, and Endocrinology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan.

Molecular and Cellular Biology
|March 5, 2008
PubMed

Insights

Tuberous sclerosis complex 2 (TSC2) deficiency in pancreatic beta cells initially increases cell size and islet mass, leading to hypoglycemia. Later, it causes cell loss, hyperglycemia, and reduced islet mass, indicating a biphasic role.

Area of Science:

  • Endocrinology
  • Cell Biology
  • Metabolic Research

Background:

  • Insulin and IGF-1 are crucial for pancreatic beta-cell mass regulation.
  • Tuberous sclerosis complex 2 (TSC2) is an upstream regulator of mTOR signaling.

Purpose of the Study:

  • To investigate the impact of TSC2 deficiency on pancreatic beta-cell function and mass.
  • To elucidate the role of TSC2 in regulating beta-cell mass dynamics.

Main Methods:

  • Generation of mice with TSC2 deficiency specifically in pancreatic beta cells (betaTSC2(-/-) mice).
  • Analysis of islet mass, beta-cell size and number, and signaling pathways (e.g., IGF-1-dependent phosphorylation).
  • Assessment of glucose and insulin levels at different ages.

Main Results:

  • Young betaTSC2(-/-) mice showed increased IGF-1 signaling, elevated p70 S6 kinase and 4E-BP1 phosphorylation, larger beta cells, increased islet mass, hypoglycemia, and hyperinsulinemia.
  • Older betaTSC2(-/-) mice developed progressive hyperglycemia and hypoinsulinemia, with a significant reduction in beta-cell number and overall islet mass.

Conclusions:

  • TSC2 plays a critical, biphasic role in regulating pancreatic beta-cell mass.
  • TSC2 deficiency initially promotes beta-cell expansion via increased cell size, followed by beta-cell loss and impaired function over time.

More Related Videos

Surgical Injury to the Mouse Pancreas through Ligation of the Pancreatic Duct as a Model for Endocrine and Exocrine Reprogramming and Proliferation07:44

Surgical Injury to the Mouse Pancreas through Ligation of the Pancreatic Duct as a Model for Endocrine and Exocrine Reprogramming and Proliferation

Published on: August 7, 2015

Related Concept Videos

Type I Diabetes II: Pathophysiology01:26

Type I Diabetes II: Pathophysiology

Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.